Genocea Biosciences has developed GEN-003, a first-in-class protein of GEN- 003 vaccine against genital herpes. Jul 24, 2017 . In this 131-subject Phase 2b clinical trial, GEN-003 reduced the median. . Inducing a T cell response against genital herpes is critical to treating of T cell immunity to develop life-changing vaccines and immunotherapies. GEN-003 is a Phase 3 ready, protein subunit T cell-enabled therapeutic vaccine intended to reduce the duration and severity of clinical symptoms associated .In March, I reported on stage II results of the first ever herpes vaccine and its effectiveness in people who were infected with herpes. Data from trials of Genocea. A biotechnology company in Australia is now recruiting participants to test a herpes vaccine aimed to both prevent and cure herpes simplex 2 infections. One of the most frustrating aspects of having genital herpes is the lack of success in past years towards a cure. The development of a vaccine for chicken pox, a. -Statistically significant result on expected Phase 3 primary endpoint with Phase 3 dose-- Positive results on multiple secondary clinical endpoints-- Potentially the. WHO AM I? My name is Bill Halford and I am an Associate Professor of Microbiology and Immunology at Southern Illinois University School of Medicine in Springfield. Good news in the world of virology. For the first time, there is a promising vaccine to treat Herpes Simplex Virus type 2 (HSV-2), commonly known as genital herpes. Herpes simplex research includes all medical research that attempts to prevent, treat, or cure herpes, as well as fundamental research about the nature of herpes. Herpes Vaccine Research by 2017 - Herpes Vaccine Update and News. Is there A Vaccine for Permanent Cure? Latest Research on Herpes Genocea Biosciences Inc. stock price, stock quotes and financial overviews from MarketWatch. Genocea Biosciences is not the only company that is working on herpes vaccine at the moment. Rational Vaccines (RVx) is a biotechnology startup that was founded two.